<DOC>
	<DOCNO>NCT01509105</DOCNO>
	<brief_summary>It observational multi-center study assess safety profile Prevenar13 use among Korean child routine clinical setting follow licensure introduction vaccine . This study design fulfill regulatory requirement new drug authorize KFDA .</brief_summary>
	<brief_title>Prevenar13 Post Market Surveillance</brief_title>
	<detailed_description>non-randomization , non-probability sampling</detailed_description>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants child age 6 week 5 year , whose legally authorize representative patient agree provide write informed consent form ( data privacy statement ) . Infants child indicate and/or contraindicate Prevenar13 usage include .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>